成人肾移植后IgA肾病复发
这项国际多中心回顾性研究纳入2005至2015年间16个中心504例活检证实的IgA肾病患者,发现肾移植后15年IgA沉积复发累积发生率为23%(95%CI 14-34),复发与移植物丢失风险增加3.69倍相关(95%CI 2.04-6.66)。
要点
- 肾移植后15年IgA肾病复发累积发生率为23%(95%CI 14-34)。
- 肾移植前预先移植和预存供者特异性抗体与复发风险升高相关。
- 复发患者移植物丢失风险增加3.69倍(95%CI 2.04-6.66)。
核心结论
- 在国际队列中,肾移植后IgA肾病复发累积风险随时间增加,并与移植物丢失风险增加3.7倍相关。
研究设计与样本
- 多中心、国际、回顾性研究,纳入2005至2015年间16个中心504例活检证实的IgA肾病患者。
主要发现
- 504例受者中82例经肾活检发现IgA沉积复发,15年累积复发率为23%(95%CI 14-34)。
- 多变量Cox回归显示预先移植(HR 3.45;95%CI 1.31-9.17)和预存供者特异性抗体(HR 2.59;95%CI 1.09-6.19)与复发风险升高相关。
- 肾移植后新发供者特异性抗体与后续IgA肾病复发风险升高相关(HR 6.65;95%CI 3.33-13.27)。
- 复发患者移植物丢失风险高于无复发患者(HR 3.69;95%CI 2.04-6.66),复发诊断后8年移植物丢失率为32%(95%CI 50-82)。
关键数值与推荐
- 免疫抑制方案(包括激素使用)在多变量分析中与IgA肾病复发无关联。
临床怎么用
- 肾移植后应监测IgA肾病复发,尤其对于预先移植或存在供者特异性抗体的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In patients with kidney failure due to IgA nephropathy, IgA deposits can recur in a subsequent kidney transplant. The incidence, effect, and risk factors of IgA nephropathy recurrence is unclear, because most studies have been single center and sample sizes are relatively small. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a multicenter, international, retrospective study to determine the incidence, risk factors, and treatment response of recurrent IgA nephropathy after kidney transplantation. Data were collected from all consecutive patients with biopsy-proven IgA nephropathy transplanted between 2005 and 2015, across 16 "The Post-Transplant Glomerular Disease" study centers in Europe, North America, and South America. RESULTS: Out of 504 transplant recipients with IgA nephropathy, recurrent IgA deposits were identified by kidney biopsy in 82 patients; cumulative incidence of recurrence was 23% at 15 years (95% confidence interval, 14 to 34). Multivariable Cox regression revealed a higher risk for recurrence of IgA deposits in patients with a pre-emptive kidney transplant (hazard ratio, 3.45; 95% confidence interval, 1.31 to 9.17) and in patients with preformed donor-specific antibodies (hazard ratio, 2.59; 95% confidence interval, 1.09 to 6.19). After kidney transplantation, development of de novo donor-specific antibodies was associated with subsequent higher risk of recurrence of IgA nephropathy (hazard ratio, 6.65; 95% confidence interval, 3.33 to 13.27). Immunosuppressive regimen was not associated with recurrent IgA nephropathy in multivariable analysis, including steroid use. Graft loss was higher in patients with recurrence of IgA nephropathy compared with patients without (hazard ratio, 3.69; 95% confidence interval, 2.04 to 6.66), resulting in 32% (95% confidence interval, 50 to 82) graft loss at 8 years after diagnosis of recurrence. CONCLUSIONS: In our international cohort, cumulative risk of IgA nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of graft loss.
引用
- Uffing A, Pérez-Saéz MJ, Jouve T, et al. Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clin J Am Soc Nephrol. 2021. PMID: 34362788. doi:10.2215/CJN.00910121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。